Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.

ABSTRACT:

Objectives

While primary treatment for high-grade serous ovarian cancer tends to be uniform - maximal debulking and platinum/taxane adjuvant chemotherapy - there is little standardization of treatment in the recurrent setting beyond the exhaustive use of platinum therapies. Using secondary data from multiple centers participating in the Cancer Genome Atlas study (TCGA), we seek to characterize clinical features, timing and serial response data to provide empirical evidence for treatment expectations in the recurrent setting.

Methods

We conducted a retrospective survival analysis of TCGA study primary and secondary patient chemotherapy regimens by characterizing the dynamics of 1119 lines of therapy comprising the treatment of 461 high-grade serous ovarian cancer patients. Al

SUBMITTER: Eng KH 

PROVIDER: S-EPMC4630152 | biostudies-literature | 2015 Nov

REPOSITORIES: biostudies-literature